Shares of CASI Pharmaceuticals Inc (NASDAQ:CASI) traded up 0.5% during trading on Wednesday . The company traded as high as $4.00 and last traded at $3.89. 186,329 shares traded hands during mid-day trading, a decline of 18% from the average session volume of 227,717 shares. The stock had previously closed at $3.91.
A number of analysts have recently commented on the stock. ValuEngine raised shares of CASI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday. BidaskClub lowered shares of CASI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 14th. Finally, HC Wainwright reissued a “buy” rating and issued a $5.00 price objective on shares of CASI Pharmaceuticals in a research report on Tuesday, January 16th.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Millennium Management LLC bought a new stake in CASI Pharmaceuticals during the fourth quarter worth $137,000. Perceptive Advisors LLC bought a new stake in CASI Pharmaceuticals during the fourth quarter worth $272,000. Renaissance Technologies LLC raised its position in CASI Pharmaceuticals by 33.4% during the fourth quarter. Renaissance Technologies LLC now owns 150,600 shares of the biotechnology company’s stock worth $489,000 after acquiring an additional 37,700 shares in the last quarter. Geode Capital Management LLC raised its position in CASI Pharmaceuticals by 488.7% during the fourth quarter. Geode Capital Management LLC now owns 225,578 shares of the biotechnology company’s stock worth $733,000 after acquiring an additional 187,263 shares in the last quarter. Finally, BlackRock Inc. raised its position in CASI Pharmaceuticals by 32.6% during the fourth quarter. BlackRock Inc. now owns 386,090 shares of the biotechnology company’s stock worth $1,254,000 after acquiring an additional 94,984 shares in the last quarter. 5.11% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: “CASI Pharmaceuticals (CASI) Trading -0.5% Higher” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/03/21/casi-pharmaceuticals-casi-trading-0-5-higher.html.
CASI Pharmaceuticals Company Profile
CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.
Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.